BOSTON, March 01, 2024 (GLOBE NEWSWIRE) -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare ...

An investigational treatment for acromegaly -- also known as gigantism -- was safe and boosted biochemical control, according to final topline findings of the phase III ACROINNOVA 2 study. Meeting the ...

May 29, 2012 (Florence, Italy) — In patients with acromegaly, long-acting-release (LAR) pasireotide (SOM230, Novartis) was more effective than octreotide LAR (Sandostatin, Novartis) at inducing ...

Please provide your email address to receive an email when new articles are posted on . An AI model correctly identified 22 of 31 adults as having acromegaly strictly based on voice recordings. The ...

Please provide your email address to receive an email when new articles are posted on . Data on several approved and investigational drugs were presented at the conference, including osilodrostat ...

SAN DIEGO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) for ...

Camurus (NASDAQ STO: CAMX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company's resubmission of the New Drug Application (NDA) for Oclaiz™ (CAM2029), ...

SAN FRANCISCO--(BUSINESS WIRE)--Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines ...